Our mission is to transform the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response.
Enabling Precision Medicine for Immuno-Oncology
Personalis, Inc. is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies.
Our patented ACE (Accuracy and Content Enhanced) Technology forms the foundation of all Personalis products. ACE Technology improves every individual step in the next-generation sequencing (NGS) process, from nucleic acid extraction, to sequencing assays, to data analytics. This makes it possible for us to achieve augmented coverage of difficult-to-sequence genomic regions that are missed with the use of conventional sequencing techniques.
Using this comprehensive approach, we provide genomic data of the highest quality and accuracy to help biopharma drive their immuno-oncology clinical and biomarker discovery programs, thus enabling the rational design and development of effective cancer immunotherapies.
Personalis was founded in 2011 as a Stanford University spin-out by a team of internationally-renown NGS thought leaders consisting of John West (our CEO), Dr. Euan Ashley, Dr. Atul Butte, Dr. Russ Altman, and Dr. Michael Snyder. Our headquarters – housing our CLIA-certified, CAP-accredited laboratory – is located in Menlo Park, CA.